GO
Loading...

Enter multiple symbols separated by commas

Life Sciences

More

  • *Index Ventures clocks up 11 transactions since 2005. Ten years on from pioneering an ultra-lean business model focused on investing in "virtual" companies with a single experimental medicine, XO1's backer Index Ventures is chalking up some notable wins. The new model has grabbed attention as venture capitalists strive to improve returns in a notoriously...

  • UniQure's shares jumped more than 55 percent on Monday after Bristol-Myers said it would pick up a 4.9 percent stake in the company. UniQure's gene therapy drug, Glyberan, went on sale last year priced at 1.1 million euros. Bayer AG struck a gene therapy deal with Dimension Therapeutics in June, while France's Sanofi SA has a long-standing tie-up with Oxford...

  • FRANKFURT, April 1- Roche, the world's largest cancer drugmaker, is ready to collaborate with rivals to find new combination therapies for multi-pronged treatments, its chief executive said. Roche is vying with rivals such as Bristol-Myers Squibb, Merck& Co and AstraZeneca to develop such immuno-oncology therapies that harness the power of the body's immune...

  • BRUSSELS, April 1- Belgian molecular diagnosis company Biocartis Group is planning a listing on Euronext Brussels to fund expansion, it said on Wednesday, seeking to take advantage of growing European interest in the sector. Europe has a far thinner line-up of promising biotech start-ups, but Belgium and the Netherlands are viewed as regional hotspots.

  • An outbreak of Ebola killed close to 10,000 people across West Africa over the last year, with Liberia, Guinea and Sierra Leone being the worst affected. Private company Mapp Biopharmaceutical and Tekmira Pharmaceuticals Corp have shown that their Ebola drugs could cure non-human primates. The other companies that are currently testing potential...

  • *China shares hit seven-year high on ambitious Silk Road project. Also Monday, Israel's Teva Pharmaceutical Industries said it would buy U.S. biopharmaceutical firm Auspex Pharmaceuticals Inc for $3.5 billion, and Ireland's Horizon Pharma Plc agreed to buy U.S. drugmaker Hyperion Therapeutics Inc for about $1.1 billion. Earlier, China unveiled details of an...

  • *Novartis commits $225 mln upfront to private biotech firm. *Novartis also picks top scientist to lead immuno-oncology. March 30- Swiss drugmaker Novartis is digging deeper into cancer immunotherapy, one of the hottest areas of drug research, through a tie-up with Aduro Biotech worth up to $750 million.

  • JERUSALEM, March 25- Israeli biopharmaceutical company BioLineRX Ltd said on Wednesday an early stage trial for a drug that uses stem cells to treat leukaemia and other blood cancers met all safety and efficacy goals. Current stem cell treatments require four or five days of injections of material from a donor to get into the bloodstream, but BioLineRX said its...

  • EXCLUSIVE-DRUG THAT CAUSED "ELEPHANT MAN" SIDE EFFECT MAKES. LONDON, March 24- An experimental drug that caused appalling side effects in a clinical trial nine years ago is back in tests for rheumatoid arthritis and is showing promise when given at a fraction of the original dose. It is a remarkable turnaround from March 2006, when six healthy volunteers given the...

  • FDA panel to discuss Ebola vaccine development in May Wednesday, 18 Mar 2015 | 8:16 AM ET

    March 18- The U.S. Food and Drug Administration said an advisory panel will discuss the development of Ebola vaccines, days after an American health worker was flown back after being tested positive for Ebola in Sierra Leone. Ebola has so far claimed about 10,000 lives in Sierra Leone, Liberia and Guinea. Other companies that are testing potential treatments for...

  • LONDON, March 16- Scientists are to test a new two-shot Ebola vaccine using an experimental shot from Britain's GlaxoSmithKline, which is already in clinical trials in Africa, and a new kind of booster from Emergent BioSolutions. The Maryland- based biotech company said on Monday its modified vaccinia Ankara Ebola Zaire vaccine would be used in an initial Phase...

  • *Siemens rises on Egyptian power deals. LONDON/ PARIS, March 16- European stocks rose on Monday and Germany's DAX hit record highs, extending their recent sharp rally as investors bet that the weakened euro would boost the region's economy and lift exporter earnings. The DAX and other European stock markets have been lifted since the start of 2015 by the European...

  • March 9- An injection for double chin reduction developed by Kythera Biopharmaceutical Inc was unanimously backed by an independent panel of experts on Monday, bringing the drug a step closer to approval by the U.S. Food and Drug Administration. The FDA typically accepts the panel's recommendations. The drug is widely expected to win approval by May 13, when the...

  • March 9- CTI BioPharma Corp's experimental blood cancer drug achieved the main goal of a late-stage study, but at least two analysts said the pill would not directly compete with Incyte Corp's treatment. "...we could see pacritinib ultimately finding a niche in the market among low platelet patients and perhaps taking incremental share away from Incyte," Wells...

  • March 9- CTI BioPharma Corp said its experimental blood cancer treatment achieved the main goal of a late-stage study, sending its shares up 24 percent in premarket trading. CTI BioPharma said nearly 18,000 patients are estimated to live with myelofibrosis in the United States. Pacritinib, one of four cancer compounds CTI BioPharma is developing, is a...

  • March 9- CTI BioPharma Corp said its experimental blood cancer treatment achieved the main goal of a late-stage study. Data from the study showed that the drug, pacritinib, was significantly better than the "best available therapy" as prescribed by the patients' physician to treat myelofibrosis. Myelofibrosis is a form of blood cancer that makes the bone marrow...

  • *Zarxio from Novartis generics unit Sandoz approved by FDA. *Copy of Amgen's white cell-boosting medicine Neupogen. The move had been expected after Zarxio, which is made by Novartis' generics unit Sandoz, won unanimous backing from an FDA panel in January.

  • Arrowhead buys Novartis' RNAi portfolio Thursday, 5 Mar 2015 | 7:34 AM ET

    March 5- Arrowhead Research Corp said it acquired Novartis AG's RNAi assets to fortify its position in the field of gene therapy that aims to wipe out disease-causing proteins. Novartis is eligible to receive $25 million in Arrowhead shares within 30 days, which would make it the second-largest shareholder based on Arrowhead's market value on Wednesday.

  • GENEVA/ LONDON, March 5- Final stage of testing of an experimental Ebola vaccine being developed by Merck and NewLink Genetics will begin in Guinea on March 7, the World Health Organization said on Thursday. All three worst-hit countries- Guinea, Liberia and Sierra Leone- aim to conduct Phase III final-stage clinical trials of experimental vaccines.

  • COPENHAGEN, March 4- Bavarian Nordic has struck a prostate cancer drug deal with Bristol-Myers Squibb that could be worth $1 billion should its trials, part of a new field in cancer treatment, be successful. The jump added over $260 million to its market value of $880 million. In that trial, patients were treated with Prostvac in addition to escalating doses of...